UA104731C2 - Ингибиторы р38 мар-киназ - Google Patents

Ингибиторы р38 мар-киназ

Info

Publication number
UA104731C2
UA104731C2 UAA201103554A UAA201103554A UA104731C2 UA 104731 C2 UA104731 C2 UA 104731C2 UA A201103554 A UAA201103554 A UA A201103554A UA A201103554 A UAA201103554 A UA A201103554A UA 104731 C2 UA104731 C2 UA 104731C2
Authority
UA
Ukraine
Prior art keywords
kinase inhibitors
map kinase
therapy
formula
treatment
Prior art date
Application number
UAA201103554A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Казухіро Іто
Пітер Стронг
Уільям Гарт Рейппорт
Пітер Джон Мюррей
Джон Кінг-Андервуд
Джонатан Гарет Уільямс
Стюарт Томас Оніонс
Саймон Крістофер Херст
Девід Мішель Адрієн Таддеі
Кетрін Елізабет Чаррон
Original Assignee
Респіверт Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104731(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Респіверт Лімітед filed Critical Респіверт Лімітед
Priority claimed from PCT/GB2009/051304 external-priority patent/WO2010038086A2/en
Publication of UA104731C2 publication Critical patent/UA104731C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
UAA201103554A 2008-10-02 2009-10-02 Ингибиторы р38 мар-киназ UA104731C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0818033.3A GB0818033D0 (en) 2008-10-02 2008-10-02 Novel compound
PCT/GB2009/051304 WO2010038086A2 (en) 2008-10-02 2009-10-02 Novel compounds

Publications (1)

Publication Number Publication Date
UA104731C2 true UA104731C2 (ru) 2014-03-11

Family

ID=40019929

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201103554A UA104731C2 (ru) 2008-10-02 2009-10-02 Ингибиторы р38 мар-киназ
UAA201103555A UA105014C2 (uk) 2008-10-02 2009-10-02 Інгібітор p38 map-кінази

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201103555A UA105014C2 (uk) 2008-10-02 2009-10-02 Інгібітор p38 map-кінази

Country Status (32)

Country Link
US (1) US8293771B2 (https=)
EP (1) EP2350047B1 (https=)
JP (1) JP5571088B2 (https=)
KR (1) KR101660266B1 (https=)
CN (1) CN102203078B (https=)
AU (1) AU2009299554B8 (https=)
CA (1) CA2738827C (https=)
CL (1) CL2011000735A1 (https=)
CO (1) CO6351785A2 (https=)
CR (1) CR20110230A (https=)
CY (1) CY1114665T1 (https=)
DK (1) DK2350047T3 (https=)
EA (1) EA019590B1 (https=)
EC (1) ECSP11010948A (https=)
ES (1) ES2428917T3 (https=)
GB (1) GB0818033D0 (https=)
HN (1) HN2011000874A (https=)
HR (1) HRP20130895T1 (https=)
ME (1) ME01604B (https=)
MX (1) MX2011003552A (https=)
MY (1) MY150611A (https=)
NI (1) NI201100062A (https=)
NZ (1) NZ591426A (https=)
PE (1) PE20110810A1 (https=)
PL (1) PL2350047T3 (https=)
PT (1) PT2350047E (https=)
RS (1) RS52979B (https=)
SI (1) SI2350047T1 (https=)
SM (1) SMT201300097B (https=)
UA (2) UA104731C2 (https=)
WO (1) WO2010038085A2 (https=)
ZA (1) ZA201103181B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
MY159230A (en) * 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
JP5670912B2 (ja) * 2008-12-11 2015-02-18 レスピバート・リミテツド p38MAPキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
GB0921730D0 (en) * 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556068B1 (en) 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
WO2011124923A2 (en) 2010-04-08 2011-10-13 Respivert Limited Novel compounds
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US8933228B2 (en) 2010-06-17 2015-01-13 Respivert, Ltd. Respiratory formulations and compounds for use therein
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
CN103917536B (zh) 2011-10-03 2016-07-06 瑞斯比维特有限公司 1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂
BR112014013178A2 (pt) * 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
KR102283876B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제로서 유용한 우레아 유도체
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3083604A1 (en) 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
ES2677595T3 (es) 2014-02-14 2018-08-03 Respivert Limited Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CA3015978A1 (en) 2016-04-06 2017-10-12 Topivert Pharma Limited Kinase inhibitors
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
US11407771B2 (en) 2018-05-30 2022-08-09 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
KR102789258B1 (ko) * 2022-10-26 2025-04-01 (의료)길의료재단 신규화합물 및 이를 유효성분으로 포함하는 폐섬유화증 예방 또는 치료용 약학 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999023091A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
ID26328A (id) 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
MXPA00006233A (es) 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
DE69836563T2 (de) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
EP1362037A1 (en) 2001-02-15 2003-11-19 Boehringer Ingelheim Pharmaceuticals Inc. Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
WO2002092576A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
US20040023961A1 (en) * 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
ATE386030T1 (de) * 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
AU2003224025A1 (en) 2002-04-05 2003-10-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg p38 kinase inhibitors for treating mucus hypersecretion
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
JP2006503025A (ja) 2002-09-05 2006-01-26 サイオス インク. p38MAPキナーゼの抑制による疼痛治療
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
DE602004030222D1 (de) 2003-02-28 2011-01-05 Bayer Healthcare Llc 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
CA2517517C (en) 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0308511D0 (en) 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US20050192314A1 (en) 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
WO2006028524A2 (en) 2004-04-29 2006-03-16 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
ATE460402T1 (de) 2004-05-12 2010-03-15 Bristol Myers Squibb Co Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1- rezeptors
PT1761520E (pt) 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1824843A2 (en) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2006068591A1 (en) 2004-12-20 2006-06-29 Astrazeneca Ab Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
GB0500435D0 (en) 2005-01-10 2005-02-16 Novartis Ag Organic compounds
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007038425A2 (en) 2005-09-27 2007-04-05 Regents Of The University Of Minnesota Anti-viral compouinds
EP1960394A2 (en) 2005-11-15 2008-08-27 Bayer HealthCare AG Pyrazolyl urea derivatives useful in the treatment of cancer
JP2009518298A (ja) 2005-12-01 2009-05-07 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療に有用な尿素化合物
PE20080538A1 (es) 2006-08-04 2008-06-18 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
KR101510356B1 (ko) * 2008-07-31 2015-04-06 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 광학 신호들을 증폭, 변조 및 검출하기 위한 나노-와이어 광학 블록 디바이스들
MY159230A (en) * 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
JP5670912B2 (ja) * 2008-12-11 2015-02-18 レスピバート・リミテツド p38MAPキナーゼ阻害剤

Also Published As

Publication number Publication date
ZA201103181B (en) 2012-10-31
WO2010038085A2 (en) 2010-04-08
CN102203078A (zh) 2011-09-28
PL2350047T3 (pl) 2013-12-31
ME01604B (me) 2014-09-20
EP2350047A2 (en) 2011-08-03
BRPI0920840A2 (pt) 2020-10-20
ES2428917T3 (es) 2013-11-12
CY1114665T1 (el) 2016-10-05
WO2010038085A3 (en) 2010-06-24
AU2009299554B2 (en) 2013-11-21
CA2738827A1 (en) 2010-04-08
ECSP11010948A (es) 2011-06-30
CA2738827C (en) 2017-02-28
EA019590B1 (ru) 2014-04-30
NZ591426A (en) 2012-12-21
NI201100062A (es) 2011-10-21
KR20110065544A (ko) 2011-06-15
US20110269800A1 (en) 2011-11-03
CL2011000735A1 (es) 2011-10-14
HK1157781A1 (en) 2012-07-06
HN2011000874A (es) 2014-02-03
KR101660266B1 (ko) 2016-09-27
CR20110230A (es) 2011-11-10
US8293771B2 (en) 2012-10-23
PE20110810A1 (es) 2011-11-08
EP2350047B1 (en) 2013-06-26
JP5571088B2 (ja) 2014-08-13
MX2011003552A (es) 2011-05-25
PT2350047E (pt) 2013-10-01
JP2012504590A (ja) 2012-02-23
SMT201300097B (it) 2013-11-08
AU2009299554B8 (en) 2013-12-12
HRP20130895T1 (en) 2013-10-25
RS52979B (sr) 2014-02-28
UA105014C2 (uk) 2014-04-10
CO6351785A2 (es) 2011-12-20
CN102203078B (zh) 2014-06-25
SI2350047T1 (sl) 2013-11-29
MY150611A (en) 2014-01-30
AU2009299554A1 (en) 2010-04-08
EA201170520A1 (ru) 2011-12-30
GB0818033D0 (en) 2008-11-05
DK2350047T3 (da) 2013-09-30

Similar Documents

Publication Publication Date Title
UA104731C2 (ru) Ингибиторы р38 мар-киназ
MY159230A (en) P38 map kinase inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
UA115320C2 (uk) Інгібітори кінази
WO2011124923A3 (en) Pyrazolyl ureas as p38 map kinase inhibitors
TN2011000293A1 (en) Protein kinase inhibitors
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MY169791A (en) Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
MX364157B (es) Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa.
MX2013012979A (es) Piridina y derivados de pirazina.
MX336381B (es) Boronatos como inhibidores de arginasa.
MX340714B (es) Inhibidores de hsp90.
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
WO2007097981A3 (en) Alpha carbolines and uses thereof
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
PH12014501278A1 (en) Kinase inhibitors